$ETNB
89bio Inc
PRICE
$3.12 ▲3.311%
Delayed Price
VOLUME
60,812
DAY RANGE
- 3.12
52 WEEK
2 - 21.47
Key Metrics
Market Cap
61.46 M
Beta
1.19
Avg. Volume
558.87 K
Shares Outstanding
20.35 M
Yield
0%
Public Float
0
Next Earnings Date
2022-08-11
Next Dividend Date
Company Information
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.
Website: www.89bio.com
HQ: ,
Related News